Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(buprenorphine naloxone)
1,237 results
  • Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach. [Journal Article]
    Addict Sci Clin Pract 2020; 15(1):2Rozylo J, Mitchell K, … Azar P
  • CONCLUSIONS: A microdosing schedule can be used to induce a patient onto buprenorphine/naloxone with no apparent withdrawal; gradually reducing illicit substance use. This case report builds on previous literature, highlighting ways to minimize barriers to induction of buprenorphine/naloxone, using a microdosing schedule and assertive outreach. Given the safety profile of buprenorphine and its potential to be a lifesaving intervention, a larger study of microdosing is indicated.
  • Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. [Journal Article]
    PLoS Med 2019; 16(12):e1003002Malta M, Varatharajan T, … Fischer B
  • CONCLUSIONS: In this carefully conducted systematic review, we found that correctional facilities should scale up OAT among incarcerated persons with OUD. The strategy is likely to decrease opioid-related overdose and mortality, reduce opioid use and other risky behaviors during and after incarceration, and improve retention in addiction treatment after prison release. Immediate OAT after prison release and additional preventive strategies such as the distribution of NLX kits to at-risk individuals upon release greatly decrease the occurrence of opioid-related overdose and mortality. In an effort to mitigate the impact of the opioid-related overdose crisis, it is crucial to scale up OAT and opioid-related overdose prevention strategies (e.g., NLX) within a continuum of treatment before, during, and after incarceration.
  • Building a Group-Based Opioid Treatment (GBOT) blueprint: a qualitative study delineating GBOT implementation. [Journal Article]
    Addict Sci Clin Pract 2019; 14(1):47Sokol R, Albanese M, … Schuman-Olivier Z
  • CONCLUSIONS: While further research on the effectiveness of GBOT and its individual implementation components is needed, the blueprint outlined here provides an initial framework to help office-based opioid treatment sites implement a successful GBOT approach and hence potentially serve as future study sites to establish efficacy of the model. This blueprint can also be used to continuously monitor how components of GBOT influence treatment outcomes, providing an empirical framework for the ongoing process of refining implementation strategies.
  • Fentanyl analogue overdose: Key lessons in management in the synthetic opioid age. [Case Reports]
    J Opioid Manag 2019 Sep/Oct; 15(5):428-432Raheemullah A, Andruska N
  • Fentanyl overdoses are growing at an alarming rate. Fentanyl is often mixed into heroin and counterfeit prescription opioid pills without the customer's knowledge and only detected upon laboratory analysis. This is problematic because fentanyl analogues like carfentanil are 10,000 times more potent than morphine and pose new challenges to opioid overdose management. A 62-year-old male with an ove…
  • Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review. [Journal Article]
    BMJ Open 2019; 9(12):e032285Leece P, Khorasheh T, … Straus SE
  • In the context of the opioid crisis in North America, the benefits of evidence-based opioid agonist treatments such as buprenorphine/naloxone have not been optimised due to low uptake. Numerous factors contribute to the underuse of buprenorphine, and theory-informed approaches to identify and address implementation barriers and facilitators are needed. This scoping review aims to characterise the…
New Search Next